Arief Lalmohamed

Arief Lalmohamed (1986) obtained his Master of Science in Pharmacy in 2010 (cum laude) at Utrecht University. He was awarded a personal NWO Mosaic grant (€ 200,000) and completed his PhD in 2014 (cum laude) at the Division of Pharmacoepidemiology and Clinical Pharmacology at Utrecht University ('Complications of hip and knee replacement surgery: a pharmacoepidemiologic approach'), in close collaboration with the Medicines and Healthcare Products Regulatory Agency (MHRA, UK), Aarhus University (Denmark) and Oxford University (UK). During his PhD, Arief was trained as a clinical pharmacologist (University Medical Center Utrecht) and an epidemiologist (University Medical Center Utrecht & McGill University Canada). In 2017, he completed his training as a clinical pharmacist at the hospital pharmacy of University Medical Center Utrecht.

Since 2016, he is head of the Clinical Drug Trials department of Pharmacy (UMC Utrecht) and is responsible for clinical pharmacological and specialized pharmeutical input in yearly 300+ clinical drug trials. In 2021, he was appointed as associate professor of pharmacoepidemiology and supervises six PhD students. He is member of the Medical Ethical Research Committee (METC) and has reviewed over 100 clinical study protocols.

He has a keen interest in education and holds a teaching position at the School of Pharmacy (Utrecht University) since 2017. He is chair of the MSc Oncology course, has co-developed the interprofessional learning platform at UMC Utrecht / Utrecht University, holds a Basic Teaching Certificate (BKO) and is actively involved in several postgraduate courses. He was nominated for several teaching and best MSc Pharmacy course awards. 

His research is focused on clinical pharmacoepidemiology, in particular real world safety and efficacy of licensed drugs and drug repurposing (i.e., identifying novel therapeutic uses for licensed drugs) within the clinical fields of 'Infection and Immunity' and 'Cancer'. He is (co)author of >50 publications in international peer reviewed scientific journals. Examples include chemotherapy dose individualization in stem cell transplantations and safety / efficacy of drugs in immuno(oncological) diseases.